PTO/S8/08s (08-03.)
Approved for use through 07/31/2006, OMB 0851-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Remove

U.S. Photo and Tuberneck Reduction Act of 1995, no persons are required to interaction of intera

	Application Number			
	Filing Date		2006-02-03	
INFORMATION DISCLOSURE	First Named Inventor	PERE	Z, Jean-Phillipe	
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit			
(Not for Submission and of or it isos)	Examiner Name			
	Attorney Docket Numb	er	38624-102552	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Date	Name of Patentee or Applicant of cited Document		Relev	s,Columns,Lines v ant Passages or F es Appear	
	1	6133347		2000-1	0-17	Vickers et al.				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines v ant Passages or F es Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	elease click the Ad	d buttor		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country	y Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,L where Relevant Passages or Rele Figures Appear	+4
	1	1991/15435	wo			1991-10-17	Aalborg Portland			
	2	0960865	EP			1999-12-01	Zell Wildshousen (	Chem		
	3	06100343	JP			1994-04-12	Nippon Solid Co.			

			Application Number							
				Filing Date				2006-02-03		
		TION DISCLOSU NT BY APPLICA		First N	Named	Inventor	PER	EZ, Jean-Phillipe		
		NIBY APPLICA		Art Ur	nit					
(1101101	Jubin	ission under or or it	,	Exam	iner Na	me				
				Attorn	ey Doc	ket Numbe	er	38624-102552		
	4	2000/06517	wo			2000-02-10		Holderbank Financiere Glarus		
	5	1996/40598	wo			1996-12-19	9	Nutrasweet Co.		
	6	1998/24734	wo			1998-06-1	1	MBT Holding		

	7	1251111	EP	2002-10-23	Kao Corp.	
	8	29915326	DE	2000-07-13	ABC Angersdorfer Bauchemie	

If you wish to add additional Foreign Patent Document citation information please click the Add button

		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Patent Abstracts of Japan, vol. 0183, no. 71 (C-1224), 13 Juillet 1994. (1994-07-13)	
	2	International Search Report of PCT/ERM/IP2008, date of combletion 7 February 2005	_

If you wisl	h to ac	d additional non-patent literature document citation information please click the Add button	Add	
		EXAMINER SIGNATURE		ī

Date Considered Examiner Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number		
		Filing Date		2006-02-03
		First Named Inventor	PER	EZ, Jean-Phillipe
		Art Unit		
		Examiner Name		
		Attorney Docket Numb	er	38624-102552

See Kind Codes of USPTO Patient Documents at <u>years USPTO,GOD</u> or MPEP 801.64. Eatler office that issued the document, by the two-letter code (WIPO Standard ST,3). For Japanese patient documents, the indication of the year of the higher of the Emperor must precede the serial number of the patient document. With all documents are preceded to the patient document. With all documents are particularly the patients or periods as endoubted on the document under WIPO Standard ST, 16 if possible. Applicant is to place a check mark there if English language translation is attached.

1		Application Number		
	INFORMATION DIGGI COURT	Filing Date		2006-02-03
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	PER	EZ, Jean-Phillipe
	(Not for submission under 37 CFR 1.99)	Art Unit		
ľ	(	Examiner Name		
		Attorney Docket Numb	er	38624-102552

## CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

√ None

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to set it hours to complete, including gathering, perpairing and submitting the complete including pathering, perpairing and submitting the complete of application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you. Pathering the complete of the process o

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission, which may related the process another examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
  - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CPR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.